{"id":7464,"date":"2025-08-08T10:34:46","date_gmt":"2025-08-08T08:34:46","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?p=7464"},"modified":"2025-08-08T10:34:46","modified_gmt":"2025-08-08T08:34:46","slug":"maic-alpine-vs-ascend","status":"publish","type":"post","link":"https:\/\/beonemedaffairs.com\/us\/7464\/maic-alpine-vs-ascend\/","title":{"rendered":"MAIC: ALPINE vs. ASCEND"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":3758,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"editor_notices":[],"footnotes":""},"categories":[4],"post-tag":[],"specialisation":[],"class_list":["post-7464","post","type-post","status-publish","format-standard","hentry","category-reading","disease_state-chronic-lymphocytic-leukemia","molecule-zanubrutinib"],"acf":{"visible_for_guests":false,"title":"MAIC: ALPINE vs. ASCEND","card_title":"MAIC: ALPINE vs. ASCEND","title_for_guests":"","summary":"MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed\/refractory CLL.","card_summary":"MAIC between ALPINE & ASCEND: A matching-adjusted indirect comparison (MAIC) was conducted using individual patient data from the ALPINE trial and aggregate data from the ASCEND trial to compare the efficacy of zanubrutinib and acalabrutinib in patients with relapsed\/refractory CLL.","summary_for_guests":"","show_popup_window_to_guests":true,"blur_thumbnail_for_guests":false,"text_app":"","text":"","content-type":4,"download_file_reading":null,"display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","motionposter":false,"webcast":"","videolange":null,"fliphtml_link":"https:\/\/online.fliphtml5.com\/elkzy\/mrcp\/","authors":"","specialisation":[],"tags":[],"visible_tags":[],"post_image":7465,"post_image_for_guests":"","related_posts":[{"id":7704,"title":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL (infographic)","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":7706,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7704\/zanubrutinib-for-the-treatment-of-patients-with-del17p-and-or-tp53-cll-sll-infographic\/","date":"2026-01-29T22:29:43","date_gmt":"2026-01-29T21:29:43"},{"id":7515,"title":"Efficacy of Zanubrutinib Versus Acalabrutinib for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":7516,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7515\/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison\/","date":"2025-09-22T12:23:13","date_gmt":"2025-09-22T10:23:13"},{"id":7479,"title":"BG-68501-101 Trial","title_guest":"","summary":"BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a\/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+\/HER2- breast cancer.","summary_guest":"","content-type":4,"post_image":7480,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7479\/bg-68501-101-trial\/","date":"2025-08-08T11:03:40","date_gmt":"2025-08-08T09:03:40"},{"id":7476,"title":"BGB-43395-101 Trial","title_guest":"","summary":"BGB-43395-101 (NCT06120283) is a Phase 1a\/1b, open-label, dose-escalation and expansion trial of BGB-43395, a selective CDK4 inhibitor, as monotherapy and in combination with fulvestrant, letrozole, or elacestrant in patients with hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer and other advanced solid tumors.","summary_guest":"","content-type":4,"post_image":7477,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7476\/bgb-43395-101-trial\/","date":"2025-08-08T11:01:48","date_gmt":"2025-08-08T09:01:48"},{"id":7473,"title":"RATIONALE-306 Trial","title_guest":"","summary":"RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).","summary_guest":"","content-type":4,"post_image":7474,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7473\/rationale-306-trial\/","date":"2025-08-08T10:59:42","date_gmt":"2025-08-08T08:59:42"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/users\/3758"}],"replies":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/comments?post=7464"}],"version-history":[{"count":1,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7464\/revisions"}],"predecessor-version":[{"id":7466,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7464\/revisions\/7466"}],"acf:term":[{"embeddable":true,"taxonomy":"category","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories\/4"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories?post=7464"},{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7464"},{"taxonomy":"specialisation","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/specialisation?post=7464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}